n CME : Your SA Journal of CPD - Feminine forever? : main topic
|Article Title||Feminine forever? : main topic|
|© Publisher:||Health and Medical Publishing Group (HMPG)|
|Journal||CME : Your SA Journal of CPD|
|Author||Tobie J. De Villiers|
|Publication Date||Nov 2004|
|Pages||609 - 612|
|Keyword(s)||Advantages, Disadvantages, Hormone therapy, Life expectancy, Menopause and Quality of life|
HT is the only proven therapy for the treatment of vasomotor symptoms of menopause. <br>Systemic or local HT prevents and treats urogenital atrophy. <br>HT prevents the early bone loss of menopause and associated fractures. <br>HT is associated with a lowered risk of colorectal cancer. <br>HT increases the risk of VTE and stroke. <br>HT should not be used for the prevention of CAD. <br>EPT is associated with an increased risk of invasive breast cancer after 5 years of therapy. <br>Progestogen is only added in the presence of a uterus in order to protect against endometrial cancer. <br>Use the lowest dose of HT for the shortest period of time.
Article metrics loading...